Follow us on:

Cizzle Biotechnology programme with US firm Bio-Techne takes major step forward (VIDEO)

Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Dr Allan Syms joins DirectorsTalk Interviews to the completion of its Evaluation Programme with Bio-Techne for Cizzle’s CIZ1B cancer biomarker.

Allan reminds us of what the CIZ1B biomarker is, how this helps with the detection of early-stage lung cancer, why is Bio-Techne a good fit for Cizzle, how Cizzle intends to build on this relationship with Bio-Techne and bring its diagnostic solution to market and how Allan sees the outlook for the company.

Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer.

You might also enjoy reading Cizzle Biotechnology's Dr Allan Syms on CIZ1B Biomarker, Partnerships and Future Plans (LON:CIZ)

Find more news, interviews, share price & company profile here for:

Share this interview

Other Interviews

More News

Cizzle Biotechnology expands in the USA with new collaboration agreements June 16, 2022
Cizzle Biotechnology annual report now available June 1, 2022
Cizzle Biotechnology significant progress during 2021 and 2022 May 30, 2022
Cizzle Biotechnology strategic alliance to develop and market early lung cancer detection in USA May 6, 2022
Cizzle Biotechnology announce further research agreement with the University of York April 11, 2022
Cizzle Biotechnology report further positive outcomes from the Arcadia Clinical Trial March 7, 2022
Cizzle Biotechnology acquisition of royalty deal in inflammatory pulmonary and cardiovascular diseases February 14, 2022
Cizzle Biotechnology royalty strategic alliance for early lung cancer detection in China February 3, 2022
Cizzle Biotechnology Strategic Alliance for Early Lung Cancer Detection in China November 25, 2021
Cizzle Biotechnology Research and Development agreement worth up to £1 million signed October 22, 2021

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.